OGE Energy Corp (OGE) News

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Revance Announces Proposed Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced a proposed underwritten public offering of $100 million of...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and...